Category list : Hepatitis B
Sort by: Newest first Oldest first A-Z Z-A
-
A day in the life of a liver intensive therapy unit pharmacist Subscription
Sara Sawieres details a typical day as lead pharmacist for the liver intensive therapy unit at King’s College Hospital.
-
An update on the management of chronic hepatitis B and C infection Subscription
Chronic hepatitis B and C infection are leading causes of liver-related morbidity and mortality worldwide. Current therapies for chronic hepatitis B virus (HBV) infection consisting of nucleos(t)ide analogues (NA) rarely lead to functional cure. With a better understanding of the HBV lifecycle, novel agents have been developed with the hope of achieving functional cure. The development of direct-acting antivirals (DAAs) for hepatitis C virus (HCV) therapy has led to ...
-
New guidance for hepatitis B vaccine shortage
Public Health England has issued “temporary” guidance that restricts providing hepatitis B immunisation to adults and children, in response to the global shortage of the vaccine.
-
World Health Organization looks to eliminate threat of hepatitis B and C Subscription
The World Health Organization’s Marc Bulterys on the agency’s efforts to eliminate viral hepatitis by scaling up screening and improving access to new and effective drugs
-
All babies to receive hepatitis B vaccination
All babies born in the UK from 1 August 2017 will be vaccinated against hepatitis B virus, health officials have announced.
-
Statins benefit patients with hepatitis B and C-related cirrhosis
Statins may benefit patients with cirrhosis of the liver caused by the Hepatitis B (HBV) or Hepatitis C (HCV) virus, according to the results of a Taiwan study published in Hepatology[1] (online, 20 March 2017).
-
Community pharmacy helps diagnose people with hepatitis C infection, study shows
Community pharmacists have the potential to identify people with undiagnosed hepatitis C infection, according to research published in Clinical Pharmacist.
-
EMA extends review of antivirals for hepatitis C Subscription
The European Medicines Agency is extending its review of direct-acting antiviral treatments for hepatitis C to look at evidence that shows they are associated with liver cancer recurrence.
-
EMA to review safety of direct-acting antivirals after reports of hepatitis B reactivation Subscription
The European Medicines Agency is to review the safety of direct-acting antivirals used to treat patients with chronic hepatitis C infection.
-
Pulmonary arterial hypertension with Pegasys Subscription
Pulmonary arterial hypertension has been added as a adverse event with unknown frequency in the summary of product characteristics for Pegasys (peginterferon alfa-2a; Roche). It states that cases of pulmonary arterial hypertension have been reported in patients with risk factors such as portal hypertension, HIV infection and cirrhosis.
Show 10 per page20 per page50 per page
